1. Home
  2. ETON vs ITIC Comparison

ETON vs ITIC Comparison

Compare ETON & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$16.71

Market Cap

498.8M

Sector

Health Care

ML Signal

HOLD

Logo Investors Title Company

ITIC

Investors Title Company

N/A

Current Price

$252.28

Market Cap

517.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ETON
ITIC
Founded
2017
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
498.8M
517.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
ETON
ITIC
Price
$16.71
$252.28
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
277.8K
20.3K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
6.32%
EPS Growth
N/A
25.81
EPS
N/A
19.00
Revenue
$70,316,000.00
$273,864,000.00
Revenue This Year
$113.27
N/A
Revenue Next Year
$36.70
N/A
P/E Ratio
N/A
$13.19
Revenue Growth
102.77
13.63
52 Week Low
$11.09
$190.20
52 Week High
$23.00
$288.98

Technical Indicators

Market Signals
Indicator
ETON
ITIC
Relative Strength Index (RSI) 49.52 41.04
Support Level $16.13 $237.90
Resistance Level $17.05 $249.78
Average True Range (ATR) 0.76 7.71
MACD 0.16 -2.57
Stochastic Oscillator 79.06 26.63

Price Performance

Historical Comparison
ETON
ITIC

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About ITIC Investors Title Company

Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.

Share on Social Networks: